What is Candel Therapeutics, Inc.'s deferred revenue?

Candel Therapeutics, Inc. (CADL) reported deferred revenue of $67K in Q1 2026.

What is the long-term trend for Candel Therapeutics, Inc.'s deferred revenue?

Over 3 years (2020 to 2025), Candel Therapeutics, Inc.'s deferred revenue has grown at a -10.7% compound annual growth rate (CAGR), from $125K to $89K.

What does deferred revenue mean?

Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.

Candel Therapeutics, Inc. CADL Deferred Revenue

Deferred Revenue at other companies

CytomX TherapeuticsCTMX

$17.88M-46.2%

RegenxbioRGNX

$5.92M-56.4%

ImmunomeIMNM

$0-100%

PrecigenPGEN

$410K-25.3%

Taysha Gene Therapies, Inc.TSHA

$5.49M-53.5%

Other financials

Income statement

See full

Revenue$31.0K0.0%

Operating income-$16.3M-100%

Net income-$8.9M-220%

EPS (diluted)-$0.14-208%

Balance sheet

See full

Cash & equivalents$194.8M+111%

Total debt$2.8M-73.9%

Total equity$138.0M+84.8%

Total assets$201.9M+111%

Cash flow

See full

Operating cash flow-$18.0M-109%

CapEx$675.0K+22,400%

Free cash flow-$18.7M-117%

Valuation

See full

Market cap$693.87M+192%

Enterprise value$501.88M+220%

P/S5,595.7×-18,674×

Profitability

See full

Operating margin-28,000.8%+15,050pp

Net margin-15,156.5%-5,064pp

FCF margin-26,383.9%+14,851pp

Returns & leverage

See full

Return on equity-51.2%-16.6pp

Debt / equity0×-0.1×

Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.

The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s deferred revenue?: Candel Therapeutics, Inc. (CADL) reported deferred revenue of $67K in Q1 2026.
What is the long-term trend for Candel Therapeutics, Inc.'s deferred revenue?: Over 3 years (2020 to 2025), Candel Therapeutics, Inc.'s deferred revenue has grown at a -10.7% compound annual growth rate (CAGR), from $125K to $89K.
What does deferred revenue mean?: Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.